SA
Go ProLog In
HRMY
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
13 analysts·Moderate coverage
63
Score
9 Buy (69%)2 Hold (15%)2 Sell (16%)
Rating Breakdown
Strong Buy
00%
Buy
969%
Hold
215%
Sell
215%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$31.00
+3.0%
Consensus
$46.00
+52.9%
Bull
$62.00
+106.0%
12-Month Target Range13 analysts
$31.00$46.00$62.00
Current $30.09Consensus
Current Price
$30.09
Upside to Consensus
$15.91

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+13.72%
EPS+20.42%
FY2028
Rev+9.73%
EPS+16.14%
FY2029
Rev+16.60%
EPS+32.08%

Earnings Surprises

Recent Analyst Actions

Feb 23, 2026Deutsche Bank
Harmony Biosciences downgraded to Hold from Buy at Deutsche Bank
Target:$31.00
+6.3%from $29.16
Feb 19, 2026Mizuho Securities
Harmony Biosciences price target raised to $50 from $46 at Mizuho
Target:$50.00
+41.7%from $35.28
Feb 11, 2026UBS
Harmony Biosciences assumed at Neutral from Buy at UBS
Target:$46.00
+21.3%from $37.93
Jan 8, 2026Truist Financial
Harmony Biosciences price target lowered to $45 from $48 at Truist
Target:$45.00
+19.8%from $37.55
Dec 1, 2025Mizuho Securities
Harmony Biosciences price target raised to $46 from $39 at Mizuho
Target:$46.00
+30.3%from $35.29
Nov 24, 2025Oppenheimer
Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) Post Mgmt Meet
Target:$62.00
+80.7%from $34.31
Oct 29, 2025Mizuho Securities
Harmony Biosciences price target raised to $36 from $35 at Mizuho
Target:$36.00
+21.5%from $29.64
Oct 15, 2025UBS
Harmony Biosciences price target lowered to $43 from $50 at UBS
Target:$43.00
+60.2%from $26.84
Sep 25, 2025H.C. Wainwright
Harmony Biosciences price target lowered to $55 from $70 at H.C. Wainwright
Target:$55.00
+103.4%from $27.04
Jul 10, 2025Goldman Sachs
Harmony Biosciences resumed with a Neutral at Goldman Sachs
Target:$33.00
-3.9%from $34.33
Apr 28, 2025UBS
Harmony Biosciences price target lowered to $48 from $55 at UBS
Target:$48.00
+63.5%from $29.36
Oct 30, 2024Goldman Sachs
Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)
Target:$28.00
-32.5%from $41.49
Oct 10, 2024Mizuho Securities
Harmony Biosciences price target raised to $52 from $42 at Mizuho
Target:$52.00
+54.8%from $33.60
Sep 10, 2024UBS
UBS starts Harmony Biosciences with Buy on Wakix growth
Target:$56.00
+51.8%from $36.89
Aug 8, 2024Mizuho Securities
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $42 at Mizuho
Target:$42.00
+25.2%from $33.55
Jun 24, 2024Oppenheimer
Oppenheimer on Harmony Biosciences Holdings Inc. (HRMY): 'WAKIX Approved for EDS in Pediatric Narcolepsy, Small But Meaningful Commercial Opportunity'
Target:$56.00
+84.3%from $30.39
May 1, 2024Needham
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $52 at Needham
Target:$52.00
+71.2%from $30.37
Apr 30, 2024Raymond James
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Raymond James
Target:$37.00
+19.7%from $30.91
Oct 14, 2022Jefferies
Harmony Biosciences upgraded to Buy from Hold at Jefferies
Target:$61.00
+28.1%from $47.63

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance